Status:
UNKNOWN
Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver Cancer
Lead Sponsor:
Zhongnan Hospital
Conditions:
Circulating Tumor Cell
Eligibility:
All Genders
18-75 years
Brief Summary
Through the screening of CTCs in patients with suspected liver cancer and liver tumor resection or liver transplantation, the number of CTCs in the blood of liver cancer patients before and after surg...
Detailed Description
1. Screen patients with suspected liver cancer Long-term exposure to liver cancer risk factors (hepatitis B carriers, past history of schistosomiasis, long-term diet of Aspergillus food, history of li...
Eligibility Criteria
Inclusion
- Primary diagnosis of suspected hepatocellular carcinoma; or liver cancer patients who have undergone liver transplantation, radical resection or ablation of liver cancer;
- Age 18-75 years old;
- ASA (risk of anesthesia) score I-II;
- The ECOG score is 0-1;
Exclusion
- In addition to hepatocellular carcinoma, patients diagnosed with other types of tumors;
- Patients with extrahepatic or lymphatic metastasis;
- Patients who still have serious complications 4 weeks after surgery;
- Patients who cannot provide informed consent;
Key Trial Info
Start Date :
January 22 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 20 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04688606
Start Date
January 22 2020
End Date
May 20 2021
Last Update
December 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071